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Recovery of Corticosteroid-induced Changes in Contractile 
Properties and Morphology of Rat Diaphragm
P. N. RICHARD DEKHUIJZEN, GHISLAINE GAYAN-RAMIREZ, ANJA BISSCHOP, VERA de BOCK, 
RENÉ DOM, and MARC DECRAMER
Respiratory Muscle Research Unit, Laboratory of Pneumology and Respiratory Division, and Departments of Neuropathology, 
University Hospital, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
Treatment with the fluorinated steroid triamcinolone (TR) induced type lib fiber atrophy and the con­
tractile profile of a slow muscle in rat diaphragm. In contrast, the nonfluorinated steroid prednisolone 
(PR) caused myogenic changes without fiber atrophy, and increased fatigability. The aim of the pres­
ent study was to investigate the extent to which these changes were reversed 2 mo after discontinua­
tion of treatm ent. Adult rats were randomly assigned to receive saline, PR 1.25 or 5 mg/kg, or TR 0.25, 
0.5, or 1 mg/kg, intramuscularly daily during 4 wk. Administration of TR resulted in severe loss of body 
weight and dose-dependent mortality. During recovery, body weight in the TR groups increased gradu­
ally, still remaining reduced compared with the other groups. Two months after discontinuation of 
treatment, diaphragm weight was increased in proportion to body weight. Twitch characteristics, max­
imal tetanic force, force-frequency curve, and fatigue resistance of isolated diaphragm bundles were 
similar in all groups. Histologic examination of the diaphragm revealed no gross abnormalities in the 
PR and TR groups. Mild bu t significant type lib fiber atrophy was still present in the diaphragm and 
gastrocnemius muscle of all TR-treated animals. In conclusion, recovery of alterations in morphology 
of respiratory and peripheral skeletal muscles induced by administration ofTR is prolonged. Dekhuij- 
zen PNR, Cayan-Ramirez C, Bisschop A, de Bock V, Dom R, Decramer M. Recovery of cortico­
steroid-induced changes in contractile properties and morphology of rat diaphragm.
AM J RESPIR CRIT CARE MED 1996;153:769-75.
Recent animal studies have demonstrated that administration of 
corticosteroids affects diaphragm structure and function (1 -7 ). 
Fluorinated steroids (e.g., triamcinolone 0.5 to 3 mg/kg intramus­
cularly and dexamethasone 1 to 7.5 mg/kg intramuscularly ad­
ministered during 1 to 7 wk) caused severe loss of body and muscle 
weight up to ~40% . This was accompanied by type lib fiber at­
rophy in the diaphragm as well as in peripheral skeletal muscles 
(1-3, 5, 7). In line with these findings, a shift in contractile prop­
erties toward the functional profile of slow muscle was observed. 
In contrast, the nonfluorinated steroid prednisolone, adminis­
tered in a dose of 5 mg/kg/day intramuscularly during 4 wk, 
caused myogenic changes in the diaphragm without fiber atro­
phy (5). Functionally, these changes were accompanied by an in­
creased tendency toward fatigue.
There are no data on to what extent these changes in animals 
are reversible after discontinuation of steroid administration. 
From observations in humans it appears that clinical recovery 
of both acute (8, 9) and chronic steroid myopathy (10, 11) may 
take several months. Whether morphologic changes have also 
disappeared at that time is unknown. This, however, is of clini­
cal significance because repetitive bursts of systemic corticoste-
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roids are frequently administered in patients with asthma and 
chronic obstructive pulmonary disease (COPD). If recovery of 
the previous course o f  steroids is not complete at the time the 
second burst is given, steroid-induced changes in the diaphragm 
may superimpose, perhaps even more so in patients with COPD 
in whom respiratory muscle function may already be compro­
mised.
The aim of the present study, therefore, was to investigate 
whether in rats contractile properties of diaphragm and morpho­
logic characteristics o f  diaphragm and gastrocnemius were still 
affected 2 mo after discontinuation of a 4-wk treatment period 
with nonfluorinated (prednisolone) and fluorinated (triamcino­
lone) steroids.
METHODS
Study Design, Animals, and Treatment
One hundred twenty adult male Wistar rats, age 14 wks, were randomized 
in quadruplets, into one o f four treatment groups: control (saline 0.05 
ml/d intramuscularly), prednisolone (PR): 1.25 mg/kg/d intramuscu­
larly, PR 5 m g/kg/d  intramuscularly, or triamcinolone diacetate (TR) 
1 m g/kg/d intramuscularly. These dosages were chosen to compare the 
effects o f  similar anti-inflammatory closes o f  fluorinated (TR 1 tng/kg) 
and nonfluorinated steroids (PR 1.25 nig/kg) (12) as well as a fourfold 
higher dose o f  the latter (PR 5 mg/kg). Animals were randomly allo­
cated to be investigated immediately after the 4-wk treatment period 
or to be followed in order to study the recovery period. The acute effects 
o f  treatment were reported in a previous communication (5). The pres­
ent study addresses the recovery o f  the induced changes.
Because 12 o f  the 15 animals in the TR 1.0 mg/kg group died during 
the active treatment period, a second series of similar experiments in 
an additional 45 rats was performed with lower dosages of TR: control
770 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 153 1996
(saline 0.05 ml/d intramuscularly), TR: 0.25 m g/kg/d intramuscularly, 
or TR: 0.5 m g/kg/d  intramuscularly.
Dilution of medication was performed such that with each injection 
all animals received approximately a similar volume (0.05 ml). During 
4 wk the animals were injected daily in the left hindlimb. After this period, 
treatment was discontinued. TWo months after discontinuation contractile 
properties, histologic, and histochemical characteristics o f the diaphragm 
were examined. During the whole study period the animals were fed ad 
libitum. They were weighed twice weekly during the treatment period, 
and once weekly during the recovery period.
Contractile Properties
Rats were anesthetized with sodium pentobarbital (Nembutal, 60 mg/kg 
intraperitoneally). Animals were tracheotomized, and a tracheal can­
nula (polyethylene tubing PE-200) was inserted. They were mechanically 
ventilated with an 0 2-enriched gas mixture (Harvard pump respirator, 
South Natick, MA).
The diaphragm was quickly removed through a laparotomy, and im­
mediately immersed in a cooled (+ 4° C), oxygenated Krebs solution 
containing (in mMol/L): NaCl 137, KC14, CaCl2 2, MgCl2 1, KH2P 0 4 1, 
N aH C 03 12, glucose 6.5. To avoid regional differences in cross-sectional 
area or fiber type proportions as much as possible, two small rectangu­
lar bundles from the middle part o f the lateral costal region were ob­
tained by dissection parallel to the long axis o f  the fibers. Silk sutures 
were tied to both ends o f the bundle to serve as anchoring points. This 
preparation was completed within 5 min. Subsequently, each bundle was 
placed within the external chamber o f a jacketed tissue bath containing 
Krebs solution, maintained at 37° C and perfused with a 95% 0 2 and 
5% C 0 2 mixture. Krebs solution was changed with each new bundle. 
One end of the bundle was tied to a rigid support, while the other was 
fastened to an isometric force transducer. Both anchoring points were 
mounted to two separate micrometers. The muscle was placed in be­
tween two large platinum stimulating electrodes.
The bundles were placed at their optimal length (L0), defined as the 
length at which peak twitch force was obtained. This was followed by 
a 15-min thermoequilibration period. Stimulations were delivered through 
a Harvard 50-5016 stimulator (Edenbridge, Kent, UK), connected in se­
ries to a power amplifier (power one model HS24-4.8; R. J. Evans, Univer­
sity o f Virginia). Stimuli were applied with a pulse duration of 0.2 ms 
and a train duration of 250 ms. Maximum twitch force was achieved 
at ±  34 V. The voltage was then increased by 20% to ensure supramax­
imal stimulation. This voltage was subsequently used during all stimu­
lations. Isometric force was measured by means o f  a Maywood force 
transducer (Maywood Ltd., Hampshire, UK). The signal was amplified 
and recorded on computer via analog to digital conversion (DT2801-A) 
using Labdat software (Labdat/Anadat; RHT-InfoDat, Montreal, Can­
ada). Signal analysis was done with Anadat.
The following measurements were performed:
TWitch characteristics: TWo twitches were recorded to determine 
maximal twitch force (Pt), time to peak tension (TPT), and half­
relaxation time (1/2RT). Average values were used for further analysis. 
Maximal tetanic force (P0): Bundles were stimulated twice tetanically 
at 160 Hz, during 250 ms in order to obtain a clear plateau in force 
generation (13, 14).
Force-frequency curve: Bundles were stimulated at the following fre­
quencies: 25,160,50,160,80,160,120, and 160 Hz (15). Each stimu­
lus was separated by a 2-min interval.
Fatigue properties: Fatigability was assessed in two different ways. 
First, force output at 160 Hz was measured after each stimulus fre­
quency during the force-frequency curve (see above). This protocol 
allowed calculation of the actual force generation as a percentage 
o f the maximal force generation at that instance (15). Second, bun­
dles were fatigued by means o f 330-ms stimulations repeated every 
second at 25 Hz during 5 min (modified after Burke and coworkers 
[16]).
The whole sequence o f this contractile protocol took approximately 
1 h. After these measurements, each muscle bundle was removed from 
the bath, keeping its length at L0. Bundle length was read from the two 
micrometers to which the bundle was mounted; its thickness and width 
were measured with a hand micrometer. The bundle was blotted dry and 
weighed. Cross-sectional area (CSA) was calculated by dividing weight 
by specific density (1.056) and muscle length. Forces were expressed per
unit CSA (3,15). Twitch-to-tetanus ratio (Pt/P0) was calculated for each 
muscle bundle.
Finally, the remaining diaphragm tissue was trimmed, blotted, and 
weighed. Parasternal muscles (including sternum and chondral parts of  
the ribs), right medial scalene muscle, and the muscles gastrocnemius 
and soleus from the right hindlimb were dissected, trimmed, blotted, 
and weighed.
Histologic and Histochemical Procedures
Muscle strips obtained from the costal region o f  the diaphragm and from 
the midbelly o f  the gastrocnemius were prepared for histopathologic ex­
amination. Muscle samples were put into “tissue glue” (Tissue-Tek, Elk- 
hard, IN) on a cork holder, with the muscle fibers oriented perpendicu­
larly to the surface o f  the cork. Proper orientation o f  the bundles was 
controlled by using magnifying glasses. Subsequently, these specimens 
were quickly frozen in isopentane cooled with liquid N 2. Serial cross- 
sections, parallel to the cork, were cut at 10-|xm thickness with a cryostat 
kept at - 2 0 °  C. Sections o f  each diaphragm and gastrocnemius were 
taken for routine hematoxylin-eosin staining.
The other serial sections were stained for myofibrillar adenosine 
triphosphatase after alkaline (pH 9.3) and acid (pH 4.5) preincubation. 
Muscle fibers were classified as type I (slow-twitch), type Ila (fast-twitch 
oxidative), or type Hb (fast-twitch glycolytic) fibers (17). Slides prein­
cubated at pH 4.5 offered the best separation o f  different fiber types, 
and were subsequently used for further analysis.
Morphometric examination was carried out with a Leica microscope 
(Leitz Laborlux S., Wetzlar, Germany) at x 2 0  magnification, connected 
to a computerized image system (Quantimet 500; Leica, Cambridge Ltd., 
UK). Areas in which fiber orientation was not transverse to the long 
axis were not analyzed. Boundaries o f  individual muscle fibers were 
delineated, and fiber CSA was determined from the number o f  pixels 
within the outlined fiber. At least 150 fibers o f  each diaphragm and deep 
(red) part o f  the gastrocnemius were used to calculate mean CSA o f all 
fiber types.
Data Analysis
Two diaphragm bundles were obtained from each animal for measure­
ments of contractile properties. Mean values from each animal were taken 
for statistical analysis. Data from the different treatment groups were 
compared, using one-way analysis o f variance. Differences between means 
were assessed using Duncan’s multiple range test. Statistical significance 
was set at p <  0.05. All analyses were performed using the S P S S /P C + 
package (18). Means ±  SD are represented in text, tables, and figures, 
unless otherwise specified.
RESULTS
Body and Muscle Weight
Body weight increased in both control and prednisolone groups 
during the treatment period (Table 1). In contrast, it decreased 
in all triamcinolone groups (p < 0.001). Mortality was observed 
only in the triamcinolone groups, and was 3 of 15 (20%), 9 of
TABLE 1 
BO DY W EIGHT*
Treatment Baseline After 4 Wk After 13 Wk
Control (A )t  311 ± 20 345 ± 27 (+11%) 399 ± 32 (+28%)*
Prednisolone 1.25 mg/kg 311 ± 14 335 ± 1 5  (+8%) 396 ± 23 (+27%)*
Prednisolone 5 mg/kg 316 ± 22 333 ± 22 (+5%) 398 ± 32 (+26%)*
Triamcinolone 1 mg/kg 312 ± 1 8  176 ± 20 (-4 4 % ) § 329 ± 18 (+5%) § II
Control (B )t  358 ± 18 381 ± 16 (+6%) 439 ± 24 (+23%)*
Triamcinolone 0.25 mg/kg 354 ± 17 236 ± 14 (-33% )§ 381 ± 26 (+ 8 % )^
Triamcinolone 0.5 mg/kg 353 ± 19 220 ± 16 (-37% )§ 357 ± 26 (+1%)1§
* Body weight is expressed in g (mean ± SD) and as percentage of baseline, 
t  Control (A): control group in the first series (A) of experiments; Control (B): control 
group in the second series (B) of experiments, 
t  p <  0,001 compared with baseline.
§ p < 0,0001 compared with baseline.
II p < 0.001 compared with control group (A).
1 p < 0.001 compared with control group (B).
---------------------------------------- ---------w  w n it f ir  -  t -  m n  in  > ■** ------------------------- ------------------ - .---------- -
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TABLE 2 
MUSCLE WEIGHT*
Treatment Diaphragm Scalenus Gastrocnemius Soleus
Control (A )t
. .. .V -------, , V.— -------------------------------- , , r — m  .............................. . 1 1 ■
mg 607 ± 77 540 ± 95 621 ± 8 2 318 ± 2 4
% BW 0.15 ±0 .02 0.14 ±0.02 0.16 ±0.02 0.08 ± 0.01
Control (B )t
mg 633 ± 71 502 ± 49 642 ± 71 331 ± 31
% BW 0.14 ±  0.01 0.12 ±0.01 0.15 ±0.02 0.09 ± 0.01
Prednisolone 1.25 mg/kg
mg 609 ± 81 524 ± 86 624 ± 73 317 ± 36
% BW 0.15 ±0 .02 0.13 ±0.02 0.16 ±0.02 0.08 ± 0.01
Prednisolone 5 mg/kg
mg 586 ± 78 489 ± 77 620 ± 8 3 323 ± 47
% BW 0.14 ± 0.02 0.12 ±0.02 0.16 ± 0.02 0.08 ± 0.01
Triamcinolone 0.25 mg/kg
mg 563 ± 611 401 1 74§ 5 5 8 ± 61 § 304 ± 29
% BW 0.15 ± 0.02 0.10 ± 0.02 0.16 ± 0.02 0.08 ± 0.01
Triamcinolone 0.5 mg/kg
mg 543141* 392 ± 58§ 555 ± 49§ 301 ± 30
% BW 0.15 ± 0.02 0.10 ±0.01 0.1610.01 0.09 ± 0.01
Triamcinolone 1 mg/kg
m9 543 ± 33* 382 ± 29* 541 1 38* 2 9 6 1 2 3
% BW 0.17 ±0.01 0.12 ±0.01 0,16 ± 0.01 0.09 ± 0.01
Definition of abbreviation: BW = body weight.
* Values are expressed as mean ±  SD.
| Control (A): control group in the first series (A) of experiments; Control (B): control group in the second series (B) of experiments. 
+ p < 0.01 compared with both control and both prednisolone groups.
§ p <  0.001 compared with both control and both prednisolone groups.
15 (60%), and 12 of 15 (80%) in the TR 0.25, 0.5, and 1 mg/kg 
groups, respectively. Mortality occurred throughout the period
control, PR 1.25 mg/kg, PR 5 mg/kg, and TR 1 mg/kg, respec­
tively. The TR group showed the smallest decline (p <  0.05 com-
of administration of triamcinolone; only one animal died (one pared with PR 5 mg/kg). In the second series of experiments, 
day) after the last administration of TR 0.5 mg/kg. Postmortem these percentage decreases in maximal tetanic force were 9.0 (1.1),
9.1 (1.2), and 9.0 (1.0), in control, TR 0.25 mg/kg and TR 0.5examination of these animals was not performed. After discon­
tinuation of steroid treatment, body weight in the triamcinolone 
groups increased gradually, reaching a final body weight approx­
imately 1 to 8% above starting body weight. No change in growth 
occurred in the prednisolone groups after discontinuation of 
treatment.
Respiratory and peripheral muscle weight are shown in Table 
2. All muscle weights were clearly reduced in the triamcinolone- 
treated animals, except for soleus weight. When corrected for 
body weight, however, muscle weights were similar in all groups.
Physical activity of the animals was not measured in a stan­
dardized fashion. Roughly estimated, no changes occurred dur­
ing the treatment and recovery period.
Diaphragmatic Contractile Properties
Bundle dimensions. Bundle dimensions were similar in all groups 
(Table 3). Bundle weight was slightly lowered in the TR 0.5 and 
in the TR 1.0 mg/kg groups.
Twitch characteristics and maximal tetanic force. No signifi­
cant differences were found in twitch characteristics among the 
different treatment groups (Table 4). The prolonged 1/2RT pre­
viously found after treatment with triamcinolone was not pres­
ent after recovery.
Force-frequency curve. The response of diaphragm strips to 
increasing stimulus frequencies is shown in Figure 1A, B. Both control (A)
when expressed in absolute values and corrected for actual max­
imal tetanic force (data not shown), no differences were observed 
between the different treatment groups.
Fatigue properties. Decline in maximal tetanic force during
mg/kg, respectively.
Fatigue run. During the low-frequency fatigue run, force gener­
ation in all groups was similar, both when expressed in absolute 
values (Figure 2A, B) or as a percentage of initial values (data 
not shown).
Histopathology and Morphometry
Histologic examination of hematoxylin-eosin stained slides 
showed a normal muscular pattern in all treatment groups.
Fiber type distribution was not changed by different treat­
ments. In general, the diaphragm consisted of ~40% type I fibers, 
~30% type I la fibers, and ~30%  type lib  fibers. In the gastroc­
nemius muscle, these percentages were ~30, ~25, and ~45% , 
respectively. Diaphragm fiber dimensions were affected differ­
ently according to the type of steroid administered. Mean CSA 
of type I, Ila, and lib  fibers were similar in both control and 
prednisolone groups (Figure 3 A, B). In all TR groups, however,
TABLE 3
DIAPHRAGM BUNDLE DIMENSIONS*
(J<-. .. -J.JJ - *1 * .  .  -  • . s I . I-. ' - . I - ■ -<*•>
Treatment
Length
(mm)
Thickness
(m/n)
Width
(m m )
Weight
(mg)
v :  . . .  .  — .v < <f. ........ •< f ■ ■ ,t I . '* I .
21.2 ±2.3  0.51 ±0.11 1.43 ±0.20  22.6 ± 4,7 
Prednisolone 1.25 mg/kg 21.4 ± 1.7 0.51 ±0.12 1 .4 4 ± 0 .I9  22.8 ± 4.3
Prednisolone 5 mg/kg 
Triamcinolone 1 mg/kg 
Control (B)
Triamcinolone 0.25 mg/kq
22.4 ± 4,8 
18,9 ± 3.9t
force-frequency protocol. In all groups force generated at 160 Triamcinolone 0.5 mg/kg 
Hz during the force-frequency stimulation procedure decreased.
20.9 ± 1.5 0.50 ±0.10 1.42 ± 0.19
19.7 ± 1 .9  0.49 ±0.11 1.41 ±0.18  
21.5 ± 2.0 0.52 ±0.12 1.45±0.22 22.5 ± 3.8
20.8 ± 2 .5  0.4910.11 1.39 ±0.21
19.8 ± 3.2 0.501 0.12 1.40±0.14
20.5 ± 4.9
18.6 ± 3.4*
r  * •  . . . .  - * *  . . . . .
I  t .  -
The percentage decreases in the first series of experiments were 
[mean (SEM)] 10.6 (1.1), 11.4 (1.2), 12.9 (1.3) and 6.7 (0.8)%, in
* Values are expressed as mean ± SD. 
t  p <  0.05 compared with control (A), 
i  p <  0.05 compared with control (B).
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TABLE 4
DIAPHRAGM ATIC C O N T R A C T ILE PROPERTIES*
------------------------------------------—  -  -  ------- --------  —■—  . . . . .  .  —  ■ ■ ■  -  -  ~  ^  1 ■ i  i  a
Pt 7
TPT V4RT Po
Treatment (kg /cm2) (ms) (ms) (kg/cm 2) Pt/Po
t  —  p .  --------- ■ —r . —  f .  . . .  t
Control (A)t 0.476 ±0.128 25.6 ± 5.3 24.8 ± 5.1 2.2B ±0.54 0.20 ± 0.04
Prednisolone 1.25 mg/kg 0.448 ±0.126 25.0 ± 6.0 24.3 ± 5.5 2.27 ±0.61 0.20 ± 0.04
Prednisolone 5 mg/kg 0.511 ±0.196 25.0 ± 5.5 24.7 ± 5.6 2.43 ± 0.48 0.21 ± 0.05
Triamcinolone 1 mg/kg 0.492 ± 0.056 25.0 ±6.5 23.8 ±4.6 2.36 ± 0.26 0.21 ± 0.04
Control (B)f 0.596 ±0.130 22.5 ± 2 ,0 23.2 ±5.3 2.43 ±0.50 0.25 ± 0.03
Triamcinolone 0.25 mg/kg 0,578 ±0,155 22.8 ± 2.1 26.1 ± 6.0 2.42 ± 0.55 0.24 ± 0.03
Triamcinolone 0.5 mg/kg 0.575 ±0.196 21.8 ± 2.1
a . ____ — -  _  _  •  . _________ a . ------------. . » - . I . . - . - . ----- ---------- — -------- - ______ — .  .___=  m m »  .  1 a a ___«  _____
24.1 ± 6.4
■ -----------—  -  *  — ~  b  .  ~  -  -  - ■ - - - i n  I d  ^  mm k _________—  >__._____ u . _______-  .  - ________ . . . . ______ ___
2.44 ±0.71 0.23 ± 0.02
Definition of abbreviations: Pt = twitch force; TPT = time to peak tension; ViRT = half-relaxation time; P0 = tetanic force; Pt/P0 =
twitch/tetanic ratio.
* Values are expressed as mean ± SD.
t Control (A): control group in the first series (A) of experiments; Control (B): control group in the second series (B) of experiments.
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type lib CSA was significantly reduced compared with the respec­
tive control groups (p < 0.05). Type I and Ila diameters were un­
affected by treatment with TR. A similar pattern of isolated type 
lib fiber atrophy was observed in the gastrocnemius in all TR 
groups (p < 0.05) (Figure 4A, B).
DISCUSSION
The present study shows the differences in recovery of steroid- 
induced changes in morphology and contractile properties of rat 
diaphragm when administering triamcinolone and prednisolone. 
Two months after discontinuation of administration of all 
dosages of triamcinolone studied, mild but significant selective 
type Mb fiber atrophy of the diaphragm is still present. Func­
tional differences are not present among the groups. Similar mor­
phologic changes are found in the gastrocnemius. In contrast, 
no histologic or functional changes are observed after complete 
withdrawal of prednisolone, which is in accord with the subtle 
changes associated with acute administration of this steroid.
Mortality induced by triamcinolone appeared to be high and
dose-related. The cause of this mortality is not clear. Severe (re­
spiratory) muscle wasting may possibly lead to respiratory fail­
ure, although we did not investigate this possibility. In addition, 
a reduction in the function of the immune system might play 
a role.
Previous animal studies have shown that treatment with fluori- 
nated steroids causes profound changes in diaphragm structure 
and function (1, 2, 4, 5, 7). In these studies diaphragm weight 
was reduced by approximately 30 to 40% as a result of type lib  
fiber atrophy, resulting in a relative predominance of fatigue- 
resistant muscle fibers. This was reflected by an increase in 1/2RT, 
prolongation of time to peak tension, and reduced fatigability 
of the diaphragm. The generalized fiber atrophy in hamsters 
found by Lewis and coworkers (4) may be explained by the young 
age (7 wk) of the animals. The acute effects of a 4-wk treatment 
period with triamcinolone 0.5 and 0.25 mg/kg/d were not inves­
tigated in the present study. The effects of 6-wk administration 
of triamcinolone 0.5 mg/kg/d, however, have recently been de­
scribed (7). Severe myogenic changes were observed in the di­
aphragm of the rats, similar to the effects described after 4 wk
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Figure 4. (A) Gastrocnemius fiber CSA in the first series of experiments (means + SD). Open bars: control; hatched bars: prednisolone 1.25 
mg/kg; solid bars: prednisolone 5 mg/kg; cross-hatched bars: triamcinolone 1 mg/kg. *p < 0.05 compared with all other groups. (B) Gastroc­
nemius fiber CSA in the second series of experiments (means + SD). Open bars: control; hatched bars: triamcinolone 0.25 mg/kg; solid bars:
triamcinolone 0.5 mg/kg. *p <  0.05 compared with control.
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administration of triamcinolone 1 mg/kg/d (5). It is conceiv- lar changes appears to be slow. After acute steroid myopathy,
able that similar changes would have occurred after a treatment electromyographic examination of peripheral skeletal muscle still
period of 4 wk. Although we did not study the acute effects of showed abnormalities 6 mo after complete withdrawal of ste-
treatment during 4 wk with triamcinolone 0.25 mg/kg/d, the re- roid treatment (8). Similarly, in chronic steroid myopathy recov-
sidual type lib fiber atrophy in this group after the follow-up ery of respiratory and peripheral muscle strength may take up
period would suggest that more pronounced type lib fiber atro- to 3 to 6 mo (9, 10). This was confirmed in a recent prospective
phy has occurred after the acute treatment period. A recent study study by Weiner and coworkers (11). These investigators studied
showed that this dose of triamcinolone caused a reduction in body the effects of prednisone 1 to 1.5 m g/kg/d administered during
weight of ~ 2 6% after a 2-wk treatment period (19). This was 8 wk in patients with no underlying lung diseases. Treatment with
accompanied by an increase in glutamine and phenylalanine ef- prednisone clearly reduced inspiratory muscle strength and en-
flux from the diaphragm, indicating an increased diaphragm pro- durance. Subsequent tapering down of the dosage to complete
tein degradation rate. The changes in body and muscle weight withdrawal within 6 wk resulted in a gradual improvement of
occurring in the present study further support the presence of respiratory muscle function. This improvement was continued
alterations in muscle structure after triamcinolone treatment. In even 6 mo after complete withdrawal (11). Histologic data with
conclusion, although we did not study the acute effects of 4 wk regard to morphologic features in respiratory or peripheral skele-
treatment with triamcinolone 0.5. and 0.25 mg/kg/d, the data tal muscles several months after discontinuation of steroids in
from previous studies and the changes in body and muscle weight patients are not available.
in the present study support the contention that acute changes Steroid-induced changes in structure and function of the di-
(i.e., type lib fiber atrophy) were likely to be present after 4 wk aphragm are of specific clinical interest in patients with COPD.
of treatment, and that persistent atrophy of these fibers present Treatment with systemic steroids is frequently indicated in these
after the 2-mo follow-up period indicates an incomplete struc- patients. Diaphragm function in these patients, however, is com-
tural recovery. promised by malnutrition (27, 28), hyperinflation (29), distur-
Changes induced by nonfluorinated steroids appear to be bances in blood gases (30), and cardiac failure (31, 32). In addi-
different, depending on the amount of steroid administered. High tion, age itself may affect respiratory muscle strength (33). It may
doses of (hydro)cortisone acetate (10 to 100 mg/kg intramuscu be expected that the effects of steroids on the already compro-
larly) also reduce diaphragm weight by approximately 30 to 40% mised diaphragm may be more pronounced (34). The unfavora-
(15, 20-22). Atrophy of all fiber types was found in rabbit di- ble effects of steroids on the diaphragm might then be enhanced
aphragm (21), whereas no morphometry was performed in the if a subsequent course of steroids would be administered before
other studies. In contrast, prednisolone, administered intramus- the diaphragm has recovered completely from the previous treat-
cularly in a dose of 5 mg/kg/d during 4 wk, caused myogenic ment with steroids. Physical inactivity, which may accompany
changes in the diaphragm, consisting of greater than normal vari- recurrent exacerbations, leads to an increase of the number of
ation of the diameter of all fiber types, excess of nuclei, and in- steroid receptors on skeletal muscle (35). If a similar mechanism
creased amount of connective tissue (5). Generalized or selective would also occur in the diaphragm and the other respiratory mus-
atrophy did not occur. Functionally, these changes were accom- cles, this would enhance the steroid-induced effects even further.
panied by an increased tendency toward fatigue. In conclusion, the present study shows that discontinuation
Bundle dimensions themselves may affect contractile prop- of triamcinolone treatment for a period of 2 mo does not allow 
erties. Segal and Faulkner (23) studied the effect of muscle thick- the diaphragm to regain its normal structure completely. The 
ness and incubation temperature on the contractile properties acute effects of prednisolone on the diaphragm, however, ap-
of rat skeletal muscles. The critical radius for 0 2 diffusion (i.e., 
the distance into a muscle at which 0 2 tension declined to zero) 
was ~0.60 mm at 37° C. This is clearly above the radius of the 
bundles in our study, which was ~0.25 mm. It seems therefore 
unlikely that the small differences in bundle weight and conse­
quent differences in oxygen diffusion would account for the ob­
served changes in contractile properties.
The pattern of recovery after cessation of fluorinated and non­
fluorinated steroids was not studied before in animal models. 
In the present study, 2 mo after discontinuation of triamcino­
lone, residual type lib fiber atrophy was still present. Appar­
ently, the degree of decrease in type lib fiber size was too small 
to result in pronounced changes in contractile properties. In con­
trast, no histologic or functional changes were observed after 
complete withdrawal of prednisolone. The latter finding is in 
agreement with the small changes associated with acute treatment.
In most of the abovementioned animal studies high or even 
massive doses of steroids were administered. Consequently, acute 
atrophy and rhabdomyolysis might have been induced in these 
studies. This has also been observed in patients with acute air­
ways obstruction, treated with massive doses of corticosteroids 
(8,24-26). This pattern of acute generalized muscle atrophy and 
weakness, however, is distinctly different from the clinical pat­
tern observed during chronic steroid myopathy. The latter oc­
curs after prolonged administration of steroids, and is charac­
terized by the insidious onset of muscle weakness predominantly 
localized in the proximal extremities (9).
In patients, recovery of both types of steroid-induced muscu-
pear to have resolved at the time of examination.
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